Abstract
Purpose Super-resolution ultrasound (SRUS) is a promising imaging modality for detecting early microvascular changes after cancer treatment, offering advantages over tumour-size methods to evaluate response. For clinical application, it is crucial to assess repeatability of SRUS-derived biomarkers and their sensitivity to post-treatment changes.
Experimental Design Clinical data were collected from breast cancer patients undergoing radiotherapy. 24 repeatability scans were conducted, and 11 participants underwent SRUS response assessment at 2-weeks and 6-months post-radiotherapy. Ultrafast CEUS acquisitions sampled four imaging planes of each tumour, generating 2D SRUS maps of microvascular structure and dynamics. SRUS-derived quantitative parameters were extracted, with repeatability assessed using the Repeatability Coefficient (RC). Changes in quantitative parameters were analysed post-radiotherapy, and the RC defined significant changes. SRUS-derived quantitative parameters were compared to histopathological CD31 staining of biopsy samples.
Results The RCs of SRUS quantitative parameters improved when averaged over more imaging planes, indicating improved repeatability. Significant changes in SRUS quantitative parameters were observed at 2-weeks post-RT in 5/11 participants. In contrast, only 1/11 participants showed significant tumour size changes. By 2-weeks or 6-months post-RT, significant changes in SRUS quantitative parameter were detected in all participants, while significant changes in tumour size were observed in 6/11 participants. Among 10 participants with corresponding CD31 vessel counts, 7 showed a correlation between the direction of change in histopathological vessel count scores and SRUS vessel density.
Conclusions This repeatability and response assessment study establishes multi-plane SRUS as a robust and sensitive tool for detecting early tumour microvascular changes in patients undergoing treatment.
Funding CRUK Convergence Science Centre, Kortuc Inc., NHS, NIHR, ICiC, IAA.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT03946202
Funding Statement
This research project and MM is supported by the CRUK Convergence Science Centre at The Institute of Cancer Research, London, and Imperial College London (A26234). MT is funded by NIHR i4i under Grant No. NIHR200972, BH is funded by China Scholarship Council, and JY is funded by Chan Zuckerberg Foundation under Grant No. 2020-225443. We acknowledge funding from Kortuc Inc., Japan, NHS funding to the NIHR Biomedical Research Centre at The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, the National Institute for Health Research (grant No. NIHR200972) and the ICiC & IAA funding from Imperial College.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was granted by the West of Scotland Research Ethics Committee (REC reference 20/WS/0019).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The authors declare no potential conflicts of interest.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
